Xoft Brain IORT

​​Marta Ortega, MD, NS, Cáceres University Hospital“We were encouraged by preliminary data supporting Xoft IORT for brain tumors, and we are impressed with the protocol of the GLIOX trial evaluating an innovative therapeutic approach to treat recurrent GBM. When we were offered the opportunity to treat patients with Xoft IORT, as well as the chance to potentially join the GLIOX trial, we immediately began using the new approach on patients with GBM and other tumor types. Although it is still early, results thus far are encouraging. This method offers hope for certain types of disease, as it may allow us to select patients for a treatment that could replace weeks of external beam radiotherapy (EBRT).”​Naveed Wagle, MD
Associate Professor of Neurosciences at the Saint John’s Cancer Institute“This is a significant milestone, not just for our institute, but also for patients with recurrent glioblastoma. The initiation of a clinical trial under normal circumstances is no small feat, but the COVID pandemic presented additional challenges that had to be overcome. It truly was an enormous achievement, and we are excited that we can now offer it to patients.”​Alexey Gaytan, MD, PhD, Neurosurgeon at the European Medical Center“Treatment options for patients with recurrent GBM are extremely limited. As such, we are encouraged by the interim results that demonstrate significant improvement in OS and locPFS in recurrent GBM patients with maximal safe resection plus Xoft Brain IORT compared to re-resection followed by various alternative adjuvant therapy options (mostly external beam re-irradiation plus chemotherapy). This innovative approach is equivalent to multiple sessions of external beam radiation therapy (EBRT), yet with minimized risk of radiation dose to neighboring healthy tissues. We encourage collaboration on further multidisciplinary, multicenter clinical trials as the initial data is promising.”​Michael Howard, PhD, DABMP, RSO, Director of Oncology Services and Chief of Medical Physics at the Sarah Cannon Cancer Institute at the Parkridge Medical Center in Chattanooga, TN“New treatments for recurrent GBM are greatly needed, and local recurrence is often inevitable after the first round of radiation therapy due to resistance to radiation. However, clinical results are beginning to reveal that Xoft Brain IORT shows significant promise for treating recurrent GBM, and we are eager to begin evaluating its feasibility and safety on patients here at the Sarah Cannon Cancer Institute.”​Santosh Kesari, MD, PhD,
Director of Neuro-oncology Chair and Professor, Department of Translational Neurosciences at Saint John's Cancer Institute in Santa Monica, CA“GBM is one of the most aggressive cancers with very poor survival and innovative approaches are needed. We are eager to open this international Phase II multi-center study using Xoft IORT as a potential new approach to local control of this devastating disease. In particular, if the results of this Phase II medical device trial confirm previously reported results, this innovative technology could rapidly be adopted since it is already cleared for use by the FDA for treatment of cancer anywhere in the body.”​Alexey Krivoshapkin, MD, PhD, Neurosurgeon at the European Medical Center (EMC) in Moscow, Russia“We are encouraged by the promising results we’ve seen using IORT to deliver the required prescribed single focal dose that is equal to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue for the treatment of recurrent GBM. While our findings concluded feasibility, more clinical trials are warranted, and we whole-heartedly applaud the collaborative efforts.”​Mehran Yusuf, MD, Radiation Oncologist at the James Graham Brown Cancer Center at the University of Louisville"We’ve treated four patients in our trial and our initial experience suggests IORT using the Xoft eBx system for treatment of large, resected brain metastases is well tolerated without unexpected early adverse treatment effects.”